| Abstrakt: |
In a triple‐blind, crossover, fixed‐dosage study, sodium butabarbital (Butisol Sodium) was tested as an aid to sleep for 53 hospitalized aged psychiatric patients with sleep disorders. After one week of placebo therapy to detect “placebo reactors,” the additional three‐week schedule (oral administration) consisted of the following sequences: (a) placebo, Butisol 50 mg, Butisol 100 mg; (b) Butisol 50 mg, Butisol 100 mg, placebo; (c) Butisol 100 mg, placebo, Butisol 50 mg. Observations were made at the first two half hours after administration of medication at 8 p.m. and hourly thereafter until 6 a.m., for onset of sleep, duration of sleep, number of times awake, duration of waking period, quality of sleep, and mental state on awakening. Three tests were used for evaluating the patients: CGI, NOSIE and TES. |
Plný text